Myelodysplastic Syndrome Clinical Trial

Long-term Study of Romiplostim in Thrombocytopenic Pediatric Patients With Immune Thrombocytopenia (ITP)

Summary

This is a phase 3b single arm, open label, multicenter study describing the percentage of time pediatric participants with ITP have a platelet response while receiving romiplostim, defined as a platelet count ≥ 50 x 10^9/L in the absence of ITP rescue medications for the past 4 weeks.

View Eligibility Criteria

Eligibility Criteria

Inclusion Criteria:

Diagnosis of primary ITP according to The American Society of Hematology (ASH) Guidelines at least 6 months before screening, regardless of splenectomy status
Age ≥ 1 year and < 18 years of age
Refractory to prior ITP therapy, relapsed after at prior ITP therapy, or be ineligible for other therapies. Examples of prior therapy include: corticosteroids, intravenous Immunoglobulin (IVIG), anti-D immunoglobulin, platelet transfusions.
Platelet count ≤ 30 x10^9/L or is experiencing uncontrolled bleeding
Has provided informed consent before any study-specific procedure;

Adequate hematologic, renal, and liver function during screening:

Hemoglobin > 10.0 g/dL
Serum creatinine ≤ 1.5 x the upper limit of normal (ULN)
Total serum bilirubin ≤ 1.5 x the ULN
Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤ 3.0 x the ULN
For the EU, Switzerland and Turkey protocol supplement, subject must agree to a scheduled bone marrow biopsy and aspirate at Year 1 or Year 2 following romiplostim treatment and any unscheduled biopsies if clinically indicated
For the EU, Switzerland and Turkey protocol supplement, a reticulin grade of 0, 1, 2, or 3 according to the modified Bauermeister grading scale, as assessed by central laboratory from a bone marrow biopsy performed within 1 year prior to planned first dose of romiplostim or consent to a pre-treatment bone marrow biopsy and aspirate prior to planned first dose of romiplostim

Exclusion Criteria:

History of a bone marrow stem cell disorder (Any abnormal bone marrow findings other than those typical of ITP must be approved by Amgen before a subject may be enrolled)
Prior bone marrow transplant or peripheral blood progenitor cell transplant
Active or prior malignancy except non-melanoma skin cancers within the last 5 years
History of myelodysplastic syndrome
History of bleeding diathesis
History of congenital thrombocytopenia
History of Hepatitis B, Hepatitis C or human immunodeficiency virus (HIV)
History of systemic lupus erythematosus, Evans syndrome, or autoimmune neutropenia
History of antiphospholipid antibody syndrome or known positive for lupus anticoagulant
History of disseminated intravascular coagulation, hemolytic uremic syndrome, or thrombotic thrombocytopenic purpura
History of venous thromboembolism or thrombotic events
Previous use of romiplostim or previous use of eltrombopag within 4 weeks of enrollment
Previous use of pegylated recombinant human megakaryocyte growth and development factor (PEG-rHuMGDF), recombinant human thrombopoietin (rHuTPO) or any other platelet producing agent
Rituximab (for any indication) or 6-mercaptopurine within 8 weeks of enrollment, or anticipated use at any time during the study
Splenectomy within 4 weeks of the screening visit
Alkylating agents within 8 weeks before the screening visit or anticipated use during the time of the proposed study
Vaccinations known to decrease platelet counts within 8 weeks before the screening visit
Currently enrolled in another investigational device or drug study, or less than 30 days since ending investigational study
Will have investigational procedures while enrolled on study
Female subject of child bearing potential (defined as having first menses) not willing to use, in combination with her partner highly effective methods of birth control during treatment and for 1 month after the end of treatment
Subject is pregnant or breast feeding, or might become pregnant within 1 month after the end of treatment
Subject has known hypersensitivity to any recombinant Escherichia coli derived product (eg, Infergen®, Neupogen®, somatropin, and Actimmune®)
Has previously enrolled into this study
Will not be available for protocol-required study visits or procedures, to the best of the subject's and investigator's knowledge
Any kind of disorder that, may compromise the subject to give written informed consent and/or to comply with all required study procedures

Study is for people with:

Myelodysplastic Syndrome

Phase:

Phase 3

Estimated Enrollment:

203

Study ID:

NCT02279173

Recruitment Status:

Completed

Sponsor:

Amgen

Check Your Eligibility

Let’s see if you might be eligible for this study.

What is your age and gender ?

Submit

There are 78 Locations for this study

See Locations Near You

Research Site
Roseville California, 95661, United States
Research Site
Atlanta Georgia, 30322, United States
Research Site
Chicago Illinois, 60611, United States
Research Site
Peoria Illinois, 61615, United States
Research Site
Indianapolis Indiana, 46260, United States
Research Site
Iowa City Iowa, 52242, United States
Research Site
Kansas City Missouri, 64108, United States
Research Site
Las Vegas Nevada, 89109, United States
Research Site
New York New York, 10021, United States
Research Site
Cincinnati Ohio, 45229, United States
Research Site
Columbus Ohio, 43205, United States
Research Site
Pittsburgh Pennsylvania, 15224, United States
Research Site
Nashville Tennessee, 37232, United States
Research Site
Dallas Texas, 75390, United States
Research Site
Fort Worth Texas, 76104, United States
Research Site
Houston Texas, 77030, United States
Research Site
Randwick New South Wales, 2031, Australia
Research Site
South Brisbane Queensland, 4101, Australia
Research Site
Parkville Victoria, 3052, Australia
Research Site
Brussels , 1020, Belgium
Research Site
Bruxelles , 1200, Belgium
Research Site
Gent , 9000, Belgium
Research Site
Leuven , 3000, Belgium
Research Site
Liege , 4000, Belgium
Research Site
Belem Pará, 66033, Brazil
Research Site
Jau São Paulo, 17210, Brazil
Research Site
Sao Paulo São Paulo, 05403, Brazil
Research Site
Sao Paulo São Paulo, 08270, Brazil
Research Site
Hamilton Ontario, L8S 4, Canada
Research Site
Toronto Ontario, M5G 1, Canada
Research Site
Montreal Quebec, H3T 1, Canada
Research Site
Montreal Quebec, H4A 3, Canada
Research Site
Olomouc , 775 2, Czechia
Research Site
Ostrava-Poruba , 708 5, Czechia
Research Site
Praha 5 , 150 0, Czechia
Research Site
Montpellier cedex 05 , 34295, France
Research Site
Nice Cedex 3 , 06202, France
Research Site
Paris , 75019, France
Research Site
Vandoeuvre les Nancy , 54511, France
Research Site
Budapest , 1094, Hungary
Research Site
Debrecen , 4032, Hungary
Research Site
Szeged , 6720, Hungary
Research Site
Beer Sheva , 84101, Israel
Research Site
Haifa , 31096, Israel
Research Site
Jerusalem , 91120, Israel
Research Site
Petach Tikvah , 49202, Israel
Research Site
Tel Aviv , 64239, Israel
Research Site
Tel Hashomer , 52621, Israel
Research Site
Monterrey Nuevo León, 64460, Mexico
Research Site
Bydgoszcz , 85-09, Poland
Research Site
Lodz , 91-73, Poland
Research Site
Olsztyn , 10-56, Poland
Research Site
Zabrze , 41-80, Poland
Research Site
Krasnodar , 35000, Russian Federation
Research Site
Moscow , 11719, Russian Federation
Research Site
Moscow , 11799, Russian Federation
Research Site
Saint-Petersburg , 19702, Russian Federation
Research Site
Saratov , 41002, Russian Federation
Research Site
Volgograd , 40013, Russian Federation
Research Site
Johannesburg Gauteng, 2013, South Africa
Research Site
Parktown Gauteng, 2193, South Africa
Research Site
Durban KwaZulu-Natal, 4001, South Africa
Research Site
Tygerberg Western Cape, 7505, South Africa
Research Site
Barcelona Cataluña, 08035, Spain
Research Site
Esplugues de Llobregat Cataluña, 08950, Spain
Research Site
Valencia Comunidad Valenciana, 46026, Spain
Research Site
Madrid , 28009, Spain
Research Site
Madrid , 28046, Spain
Research Site
Basel , 4056, Switzerland
Research Site
St. Gallen , 9006, Switzerland
Research Site
Zuerich , 8032, Switzerland
Research Site
Adana , 01130, Turkey
Research Site
Antalya , 07059, Turkey
Research Site
Izmir , 35100, Turkey
Research Site
Birmingham , B4 6N, United Kingdom
Research Site
Edinburgh , EH9 1, United Kingdom
Research Site
London , W12 0, United Kingdom
Research Site
Manchester , M13 9, United Kingdom

How clear is this clinincal trial information?

Study is for people with:

Myelodysplastic Syndrome

Phase:

Phase 3

Estimated Enrollment:

203

Study ID:

NCT02279173

Recruitment Status:

Completed

Sponsor:


Amgen

How clear is this clinincal trial information?

×

Introducing, the Journey Bar

Use this bar to access information about the steps in your cancer journey.

Please confirm you are a US based health care provider:

Yes, I am a health care Provider No, I am not a health care provider